THIRA Health Welcomes Patricia Charles-Heathers, Ph.D., MPA, as New Executive Director

1 year ago

Seasoned Behavioral Health Leader Joins THIRA Health, Strengthening Commitment to Comprehensive Mental Health Care for Women and AdolescentsBELLEVUE, WA /…

DuneGlass Capital Announces the Launch of Aviva Aesthetics: The Industry’s Only Entrepreneur-Owned and Led Medical Aesthetics Platform

1 year ago

Aviva Aesthetics provides med spa owners with an alternative to private equity CHICAGO, IL and FULTON, MD / ACCESSWIRE /…

Cosmos Health Reports Q3 2024 Results: Resilient Revenue and Gross Profit Amid 18.6% Expense Reduction; Stockholders’ Equity Up 8.8% to $35M

1 year ago

Stable revenue and gross profit despite cost-cutting initiatives, indicating the strength of underlying segments and brands.Solid liquidity position, with cash…

CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results

1 year ago

Primary analysis data in potentially pivotal GBM study with lead program, Berubicin, on track for the first half of 2025Company…

CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results

1 year ago

BEIJING, CHINA / ACCESSWIRE / November 15, 2024 / CASI Pharmaceuticals, Inc. (Nasdaq:CASI) ("CASI" or the "Company"), a Cayman incorporated…

Justera Health Announces Management Change

1 year ago

TORONTO, ON / ACCESSWIRE / November 15, 2024 / Justera Health Ltd. (CSE:VTAL)(OTC PINK:SCRSF) ("Justera"or the"Company") is pleased to announce…

Encision Reports Second Quarter Fiscal Year 2025 Results

1 year ago

BOULDER, CO / ACCESSWIRE / November 15, 2024 / Encision Inc. (OTC PINK:ECIA), a medical device company owning patented Active…

Theralase(R) Closes Non-Brokered Private Placement

1 year ago

TORONTO, ON / ACCESSWIRE / November 15, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage…

Samsung Bioepis Receives Positive CHMP Opinion for Denosumab Biosimilars, OBODENCE™ and XBRYK™

1 year ago

OBODENCE™ and XBRYK™ recommended for approval by the European Medicines Agency for all indications referencing Prolia and Xgeva, respectivelyINCHEON, South…